We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

52 hedge funds and large institutions have $32.2M invested in Enzo Biochem, Inc. in 2013 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 20 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $27.5M → $32.2M (+$4.65M)

17% less funds holding

Funds holding: 6352 (-11)

50% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 20

69% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 16

91% less call options, than puts

Call options by funds: $9K | Put options by funds: $95K

Holders
52
Holders Change
-11
Holders Change %
-17.46%
% of All Funds
1.69%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
10
Reduced
20
Closed
16
Calls
$9K
Puts
$95K
Net Calls
-$86K
Net Calls Change
-$32K
Name Holding Trade Value Shares
Change
Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$64K -$4.98K -2,100 -8%
State Street
27
State Street
Massachusetts
$60K -$33 -14 -0.1%
JP Morgan Chase
28
JP Morgan Chase
New York
$54K -$711 -300 -1%
RFC
29
Russell Frank Company
Washington
$50K
PPA
30
Parametric Portfolio Associates
Washington
$45K -$1.49K -629 -3%
FTIOP
31
Fiduciary Trust International of Pennsylvania
Pennsylvania
$40K
GC
32
Guggenheim Capital
Illinois
$36K +$4.81K +2,027 +17%
T. Rowe Price Associates
33
T. Rowe Price Associates
Maryland
$33K
Citadel Advisors
34
Citadel Advisors
Florida
$33K +$6.91K +2,914 +29%
VKH
35
Virtu KCG Holdings
New York
$27K +$25.4K +10,707 New
U
36
UBS
Switzerland
$25K -$6.21K -2,617 -21%
Bank of America
37
Bank of America
North Carolina
$22K -$5.07K -2,137 -20%
BA
38
BlackRock Advisors
Delaware
$20K
Group One Trading
39
Group One Trading
Illinois
$18K +$16.9K +7,145 New
Barclays
40
Barclays
United Kingdom
$13K -$13.4K -5,655 -46%
LTFS
41
Ladenburg Thalmann Financial Services
Florida
$9K
TJHA
42
Thomas J. Herzfeld Advisors
Florida
$8K
Wells Fargo
43
Wells Fargo
California
$3K -$1.76K -744 -33%
HCM
44
Horrell Capital Management
Arkansas
$3K
AIG
45
American International Group
New York
$2.52K -$6.89K -2,907 -74%
Ameriprise
46
Ameriprise
Minnesota
$2K -$294K -123,863 -99%
CPA
47
Cowen Prime Advisors
New York
$1K
HI
48
Hudock Inc
Pennsylvania
$1K
Manulife (Manufacturers Life Insurance)
49
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4
New York State Teachers Retirement System (NYSTRS)
50
New York State Teachers Retirement System (NYSTRS)
New York
-$268K -128,652 Closed

ENZ Hedge Fund Activity: Q3 2013 in Review

52 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q3 2013, worth a combined $32.2M — up 17% from $27.5M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of ENZ and 5 opened new positions — a net loss of 11 holders — while 20 trimmed existing stakes and 10 added.

The largest buyer was Verition Fund Management, opening a new position worth an estimated $237K. The largest seller was Ameriprise, cutting an estimated $294K.

  • 52 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q3 2013, down from 63 in Q2 2013.
  • Funds reported $32.2M of Enzo Biochem, Inc. stock for Q3 2013, up 17% quarter-over-quarter.
  • 5 funds opened new Enzo Biochem, Inc. positions in Q3 2013 and 16 closed out, a net change of -11 holders.
  • The largest Enzo Biochem, Inc. buyer in Q3 2013 was Verition Fund Management, an estimated $237K added.
  • The largest Enzo Biochem, Inc. seller in Q3 2013 was Ameriprise, an estimated $294K sold.

Based on aggregated 13F filings for Q3 2013.